Picard Medical (PMI) 8-K on stock price volatility, Oct 24, 2025

Q: What is Exhibit 99.1 in PMI’s filing?

It is the press release dated October 24, 2025 that discusses the company’s recent stock price volatility.

Q: Where does PMI’s stock trade and under what symbol?

Picard Medical’s common stock trades on the NYSE American under the symbol PMI.

Q: Who signed the 8-K for Picard Medical?

The filing was signed by Patrick NJ Schnegelsberg, Chief Executive Officer.

Q: When was the press release issued?

The press release was issued on October 24, 2025.

Picard Medical, Inc. filed a Form 8-K stating it furnished a press release discussing the volatility of its stock price.

Accepted by SEC EDGAR 10/24/2025 - 09:16 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Picard Medical, Inc. filed a Form 8-K stating it furnished a press release discussing the volatility of its stock price. The press release is included as Exhibit 99.1 and dated October 24, 2025.

The company’s common stock trades on the NYSE American under the symbol PMI. No financial results or transactions are described in this filing.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Picard Medical (PMI) report in its 8-K?

The company furnished a press release discussing the volatility of its stock price and attached it as Exhibit 99.1.

What is Exhibit 99.1 in PMI’s filing?

It is the press release dated October 24, 2025 that discusses the company’s recent stock price volatility.

Does the 8-K include financial results or new transactions?

No. The filing describes the press release about stock price volatility and includes it as Exhibit 99.1.

Where does PMI’s stock trade and under what symbol?

Picard Medical’s common stock trades on the NYSE American under the symbol PMI.

Who signed the 8-K for Picard Medical?

The filing was signed by Patrick NJ Schnegelsberg, Chief Executive Officer.

When was the press release issued?

The press release was issued on October 24, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 24, 2025

Picard Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-42801

86-3212894

(State or other jurisdiction

of incorporation)

(Commission
File Number)

(IRS Employer

Identification No.)

1992 E Silverlake
Tucson AZ, 85713

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (520) 545-1234

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PMI		The NYSE American, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.

Regulation FD Disclosure.

On October 24, 2025, Picard Medical, Inc. issued a press release discussing the volatility of its stock price. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference herein.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1		Picard Medical, Inc. Press Release dated October 24, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Picard Medical, Inc.

By:	/s/ Patrick NJ Schnegelsberg
	Name:	Patrick NJ Schnegelsberg
	Title:	Chief Executive Officer

Dated: October 24, 2025

Source: View Original Filing on SEC EDGAR